Metals and metal compounds in cancer treatment

Anticancer Research

Volumn 24, Issue 3 A, 2004, Pages 1529-1544

  Desoize, Bernard ^a  

^a UNIVERSITÉ DE REIMS CHAMPAGNE ARDENNE   (France)

Author keywords

Anti cancer drugs; Antimony; Arsenic; Bismuth; Gallium; Gold; Iron; Platinum; Review; Rhodium; Titanium; Vanadium

Indexed keywords

ANTIMONY; ARSENIC; AURANOFIN; BISMUTH; BLEOMYCIN; CARBOPLATIN; DEFEROXAMINE; FERROCENE DERIVATIVE; GALLIUM; GOLD; IRON; MERCAPTOPURINE; METAL; NEDAPLATIN; OXALIPLATIN; PLATINUM; RHODIUM; TITANIUM; TITANOCENE; TITANOCENE DICHLORIDE; VANADIUM;

ANTINEOPLASTIC ACTIVITY; BRACHYTHERAPY; BREAST CARCINOMA; GASTROINTESTINAL SYMPTOM; HEAD AND NECK CANCER; HELICOBACTER PYLORI; HUMAN; INSULIN LIKE ACTIVITY; IRON OVERLOAD; LEUKOPENIA; MULTIDRUG RESISTANCE; NEPHROTOXICITY; NONHODGKIN LYMPHOMA; OVARY CARCINOMA; OXIDATIVE STRESS; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; REVIEW; RHEUMATOID ARTHRITIS; SENSORY NEUROPATHY; STOMACH LYMPHOMA; THROMBOCYTOPENIA;

ANIMALS; HUMANS; METALS; NEOPLASMS; ORGANOMETALLIC COMPOUNDS;

EID: 3242713246     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (211)

1. Kopf-Maier P: Complexes of metals other than platinum as antitumour agents. Eur J Clin Pharmacol 47: 1-16, 1994.
2. Pelicano H, Feng L, Zhou Y, Carew JS, Hileman EO, Plunkett W, Keating MJ and Huang P: Inhibition of mitochondrial respiration: A novel strategy to enhance drug-induced apoptosis in human leukemia cells by an ROS-mediated mechanism. J Biol Chem 278: 37832-37839, 2003.
3. Huang P, Feng L, Oldham EA, Keating MJ and Plunkett W: Superoxide dismutase as a target for the selective killing of cancer cells. Nature 407: 390-395, 2000.
4. Feng CO, Ma WL and Zheng WL: Research advances on effect of arsenic trioxide on tumor. Ai Zheng 21: 1386-1389, 2002.
5. Liu O, Hilsenbeck S and Gazitt Y: Arsenic trioxide-induced apoptosis in myeloma cells: p53-dependent G1 or G2/M cell cycle arrest, activation of caspase 8 or caspase 9 and synergy with APO2/TRAIL. Blood 101: 4078-4087, 2003.
6. Hyun PW, Hee CY, Won JC, Oh PJ, Kim K, Hyuck IY, Lee MH, Ki KW and Park K: Arsenic trioxide inhibits the growth of A498 renal cell carcinoma cells via cell cycle arrest or apoptosis. Biochem Biophys Res Commun 300: 230-235, 2003.
7. Li D, Du C, Lin Y and Wu M: Inhibition of growth of human nasopharyngeal cancer xenografts in SCID mice by arsenic trioxide. Tumori 88: 522-526, 2002.
8. Guillemin MC, Raffoux E, Vitoux D, Kogan S, Soilihi H, Lallemand-Breitenbach V, Zhu J, Janin A, Daniel MT, Gourmel B, Degos L, Dombret H, Lanotte M and De The H: In vivo activation of cAMP signaling induces growth arrest and differentiation in acute promyelocytic leukemia. J Exp Med 196: 1373-1380, 2002.
9. 3. Int J Mol Med 11: 479-484, 2003.
10. Shi Y, Liu Y, Huo J and Gao G: Arsenic trioxide induced apoptosis and expression of p53 and bcl-2 genes in human small cell lung cancer cells. Zhonghua Jie He He Hu Xi Za Zhi 25: 665-666, 2002.
11. Zhao Z, Huang C, Wang J, Jiang H, Li J and Wang X: Effect of arsenic trioxide on inhibition of restenosis after rabbit vascular injury and its mechanism. Chin Med J (Engl) 115: 1608-1614, 2002.
12. Duyndam MC, Hulscher ST, Van Der WE, Pinedo HM and Boven E: Evidence for a role of p38 kinase in hypoxia-inducible factor 1-independent induction of vascular endothelial growth factor expression by sodium arsenite. J Biol Chem 278: 6885-6895, 2003.
13. Sturlan S, Baumgartner M, Roth E and Bachleitner-Hofmann T: Docosahexaenoic acid enhances arsenic trioxide-mediated apoptosis in arsenic trioxide-resistant HL-60 cells. Blood 101: 4990-4997, 2003.
14. Yeh JY, Cheng LC, Ou BR, Whanger DP and Chang LW: Differential influences of various arsenic compounds on glutathione redox status and antioxidative enzymes in porcine endothelial cells. Cell Mol Life Sci 59: 1972-1982, 2002.
15. Li J, Chen P, Sinogeeva N, Gorospe M, Wersto RP, Chrest FJ, Barnes J and Liu Y: Arsenic trioxide promotes histone H3 phosphoacetylation at the chromatin of CASPASE-10 in acute promyelocytic leukemia cells. J Biol Chem 277: 49504-49510, 2002.
16. Verma A, Mohindru M, Deb DK, Sassano A, Kambhampati S, Ravandi F, Minucci S, Kalvakolanu DV and Platanias LC: Activation of Rac1 and the p38 mitogen-activated protein kinase pathway in response to arsenic trioxide. J Biol Chem 277: 44988-44995, 2002.
17. Waalkes MP: Cadmium carcinogenesis in review. J Inorg Biochem 79: 241-244, 2000.
18. Gourdier I, Del Rio M, Crabbe L, Candeil L, Copois V, Ychou M, Auffray C, Martineau P, Mechti N, Pommier Y and Pau B: Drug specific resistance to oxaliplatin is associated with apoptosis defect in a cellular model of colon carcinoma. FEBS Lett 529: 232-236, 2002.
19. Huang MJ, Hsieh RK, Lin CP, Chang IY and Liu HJ: The cytotoxicity of arsenic trioxide to normal hematopoietic progenitors and leukemic cells is dependent on their cell-cycle status. Leuk Lymphoma 43: 2191-2199, 2002.
20. Du CW, Li DR, Lin YC and Wu MY: Arsenic trioxide induces differentiation of human nasopharyngeal carcinoma in BALB/C nude mice xenograft model. Ai Zheng 22: 21-25, 2003.
21. Mayorga J, Richardson-Hardin C and Dicke KA: Arsenic trioxide as effective therapy for relapsed acute promyelocytic leukemia. Clin J Oncol Nurs 6: 341-346, 2002.
22. Kang YJ: New understanding in cardiotoxicity. Curr Opin Drug Discov Devel 6: 110-116, 2003.
23. Bahlis NJ, McCafferty-Grad J, Jordan-McMurry I, Neil J, Reis I, Kharfan-Dabaja M, Eckman J, Goodman M, Fernandez HF, Boise LH and Lee KP: Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma. Clin Cancer Res 8: 3658-3668, 2002.
24. Kumana CR, Au WY, Lee NS, Kou M, Mak RW, Lam CW and Kwong YL: Systemic availability of arsenic from oral arsenic-trioxide used to treat patients with hematological malignancies. Eur J Clin Pharmacol 58: 521-526, 2002.
25. Muller S, Miller WH Jr and Dejean A: Trivalent antimonials induce degradation of the PML-RAR oncoprotein and reorganization of the promyelocytic leukemia nuclear bodies in acute promyelocytic leukemia NB4 cells. Blood 92: 4308-4316, 1998.
26. 2O (dtpa=diethylenetriamine- pentaacetic acid). Main Group Metal Chem 20: 169-180, 1997.
27. Keppler BK, Silvestru C and Haiduc I: Antitumor organometallics. III. In vivo activity of diphenylantimony(III) and diorganotin(IV) dithiophosphorus derivatives against P388 leukemia. Metal-Based Drugs 1: 73-77, 1994.
28. Tiekink ER: Antimony and bismuth compounds in oncology. Crit Rev Oncol Hematol 42: 217-224, 2002.
29. Lecureur V, Le Thiec A, Le Meur A, Amiot L, Drenou B, Bernard M, Lamy T, Fauchet R and Fardel O: Potassium antimonyl tartrate induces caspase- and reactive oxygen species-dependent apoptosis in lymphoid tumoral cells. Br J Haematol 119: 608-615, 2002.
30. Sampayo-Reyes A, Zakharyan RA, Healy SM and Aposhian HV: Monomethylarsonic acid reductase and monomethylarsonous acid in hamster tissue. Chem Res Toyicol 13: 1181-1186, 2000.
31. Naredi P, Heath DD, Enns RE and Howell SB: Cross-resistance between cisplatin, antimony potassium tartrate, and arsenite in human tumor cells. J Clin Invest 95: 1193-1198, 1995.
32. Vernhet L, Courtois A, Allain N, Payen L, Anger JP, Guillouzo A and Fardel O: Overexpression of the multidrug resistance-associated protein (MRP1) in human heavy metal-selected tumor cells. FEBS Lett 443: 321-325, 1999.
33. Steinbach G, Ford R, Glober G, Sample D, Hagemeister FB, Lynch PM, McLaughlin PW, Rodriguez MA, Romaguera JE, Sarris AH, Younes A, Luthra R, Manning JT, Johnson CM, Lahoti S, Shen Y, Lee JE, Winn RJ, Genta RM, Graham DY and Cabanillas FF: Antibiotic treatment of gastric lymphoma of mucosa-associated lymphoid tissue. An uncontrolled trial. Ann Intern Med 131: 88-95, 1999.
34. Kondo Y, Satoh M, Imura N and Akimoto M: Tissue-specific induction of metallothionein by bismuth as a promising protocol for chemotherapy with repeated administration of cis-diamminedichloro-platinum (II) against bladder tumor. Anticancer Res 12: 2303-2307, 1992.
35. Nikula TK, McDevitt MR, Finn RD, Wu C, Kozak RW, Garmestani K, Brechbiel MW, Curcio MJ, Pippin CG, Tiffany-Jones L, Geerlings MW, Sr, Apostolidis C, Molinet R, Geerlings MW Jr, Gansow OA and Scheinberg DA: Alpha-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: pharmacokinetics, bioactivity, toxicity and chemistry. J Nucl Med 40: 166-176, 1999.
36. McDevitt MR, Finn RD, Ma D, Larson SM and Scheinberg DA: Preparation of alpha-emitting 213Bi-labeled antibody constructs for clinical use. J Nucl Med 40: 1722-1727, 1999.
37. Fries JF, Bloch D, Spitz P and Mitchell DM: Cancer in rheumatoid arthritis: a prospective long-term study of mortality. Am J Med 78: 56-59, 1985.
38. Tiekink ER: Gold derivatives for the treatment of cancer. Crit Rev Oncol Hematol 42: 225-248, 2002.
39. Berners-Price SJ, Mirabelli CK, Johnson RK, Mattern MR, McCabe FL, Faucette LF, Sung CM, Mong SM, Sadler PJ and Crooke ST: In vivo antitumor activity and in vitro cytotoxic properties of bis [1,2-bis(diphenylphosphino) ethane]gold(I) chloride. Cancer Res 46: 5486-5493, 1986.
40. Berners-Price SJ, Girard GR, Hill DT, Sutton BM, Jarrett PS, Faucette LF, Johnson RK, Mirabelli CK and Sadler PJ: Cytotoxicity and antitumor activity of some tetrahedral bis(diphosphino)gold(I) chelates. J Med Chem 33: 1386-1392, 1990.
41. Rush GF, Smith PF, Hoke GD, Alberts DW, Snyder RM and Mirabelli CK: The mechanism of acute cytotoxicity of triethylphosphine gold(I) complexes. II. Triethylphosphine gold chloride-induced alterations in mitochondrial function. Toxicol Appl Pharmacol 90: 391-400, 1987.
42. Hoke GD, Macia RA, Meunier PC, Bugelski PJ, Mirabelli CK, Rush GF and Matthews WD: In vivo and in vitro cardiotoxicity of a gold-containing antineoplastic drug candidate in the rabbit. Toxicol Appl Pharmacol 100: 293-306, 1989.
43. Hoke GD, Rush GF, Bossard GF, McArdle JV, Jensen BD and Mirabelli CK: Mechanism of alterations in isolated rat liver mitochondrial function induced by gold complexes of bidentate phosphines. J Biol Chem 263: 11203-11210, 1988.
44. Carotti S, Marcon G, Marussich M, Mazzei T, Messori L, Mini E and Orioli P: Cytotoxicity and DNA binding properties of a chloro glycylhistidinate gold(III) complex (GHAu). Chem Biol Interact 125: 29-38, 2000.
45. Cory JG, Cory AH, Rappa G, Lorico A, Liu MC, Lin TS and Sartorelli AC: Inhibitors of ribonucleotide reductase. Comparative effects of amino- and hydroxy-substituted pyridine-2-carboxaldehyde thiosemicarbazones. Biochem Pharmacol 48: 335-344, 1994.
46. DeConti RC, Toftness BR, Agrawal KC, Tomchick R, Mead JA, Bertino JR, Sartorelli AC and Creasey WA: Clinical and pharmacological studies with 5-hydroxy-2-formylpyridine thiosemicarbazone. Cancer Res 32: 1455-1462, 1972.
47. Liu MC, Lin TS and Sartorelli AC: Synthesis and antitumor activity of amino derivatives of pyridine-2-carboxaldehyde thiosemicarbazone. J Med Chem 35: 3672-3677, 1992.
48. Coronnello M, Marcon G, Carotti S, Caciagli B, Mini E, Mazzei T, Orioli P and Messori L: Cytotoxicity, DNA damage, and cell cycle perturbations induced by two representative gold(III) complexes in human leukemic cells with different cisplatin sensitivity. Oncol Res 12: 361-370, 2000.
49. Baker E, Vitolo ML and Webb J: Iron chelation by pyridoxal isonicotinoyl hydrazone and analogues in hepatocytes in culture. Biochem Pharmacol 34: 3011-3017, 1985.
50. Djordjevitz C: Antitumor activity of vanadium compounds. In: Metal Ions in Biological Systems (Sigel H, Sigel A). New-York, Marcel-Decker, 595-616, 1995.
51. English LH, Macara IG and Cantley LC: Vanadium stimulates the (Na+,K+) pump in friend erythroleukemia cells and blocks erythropoiesis. J Cell Biol 97: 1299-1302, 1983.
52. Thompson HJ, Chasteen ND and Neeker LD: Dietary vanadyl(IV) sulfate inhibits chemically-induced mammary carcinogenesis. Carcinogenesis 5: 849-851, 1984.
53. Tsiani E and Fardel O: Vanadium compounds. Biological actions and potential as pharmacological agents. Trends Endocrinol Metab 8: 51-58, 1997.
54. Goldwaser I, Gefel D, Gershonov E, Fridkin M and Shechter Y: Insulin-like effects of vanadium: basic and clinical implications. J Inorg Biochem 80: 21-25, 2000.
55. Brichard SM and Henquin JC: The role of vanadium in the management of diabetes. Trends Pharmacol Sci 16: 265-270, 1995.
56. Hanauske U, Hanauske AR, Marshall MH, Muggia VA and Von Hoff DD: Biphasic effect of vanadium salts on in vitro tumor colony growth. Int J Cell Cloning 5: 170-178, 1987.
57. Zhang Z, Chen F, Huang C and Shi X: Vanadate induces G2/M phase arrest in p53-deficient mouse embryo fibroblasts. J Environ Pathol Toxicol Oncol 21: 223-231, 2002.
58. Krejsa CM, Nadler SG, Esselstyn JM, Kavanagh TJ, Ledbetter JA and Schieven GL: Role of oxidative stress in the action of vanadium phosphotyrosine phosphatase inhibitors. Redox independent activation of NF-kappaB. J Biol Chem 272:11541-11549, 1997.
59. Elberg G, Li J and Shechter Y: Vanadium activates or inhibits receptor and non-receptor protein tyrosine kinases in cell-free experiments, depending on its oxidation state. Possible role of endogenous vanadium in controlling cellular protein tyrosine kinase activity. J Biol Chem 269: 9521-9527, 1994.
60. Rizk SL and Sky-Peck HH: Comparison between concentrations of trace elements in normal and neoplastic human breast tissue. Cancer Res 44: 5390-5394, 1984.
61. 2 and vanadate in vitro. Biochem Biophys Res Commun 188: 773-779, 1992.
62. Posner BI, Faure R, Burgess JW, Bevan AP, Lachance D, Zhang-Sun G, Fantus IG, Ng JB, Hall DA and Lum BS: Peroxovanadium compounds. A new class of potent phosphotyrosine phosphatase inhibitors which are insulin mimetics. J Biol Chem 269: 4596-4604, 1994.
63. Bevan AP, Drake PG, Yale JF, Shaver A and Posner BI: Peroxovanadium compounds: biological actions and mechanism of insulin-mimesis. Mol Cell Biochem 153: 49-58, 1995.
64. Bevan AP, Burgess JW, Yale JF, Drake PG, Lachance D, Baquiran G, Shaver A and Posner BI: In vivo insulin mimetic effects of pV compounds: role for tissue targeting in determining potency. Am J Physiol 268: E60-E66, 1995.
65. Evangelou AM: Vanadium in cancer treatment. Crit Rev Oncol Hematol 42: 249-265, 2002.
66. Harding MM and Mokdsi G: Antitumour metallocenes: structure-activity studies and interactions with biomolecules. Curr Med Chem 7: 1289-1303, 2000.
67. Faure R, Vincent M, Dufour M, Shaver A and Posner BI: Arrest at the G2/M transition of the cell cycle by protein-tyrosine phosphatase inhibition: studies on a neuronal and a glial cell line. J Cell Biochem 59: 389-401, 1995.
68. Jaspers I, Samet JM, Erzurum S and Reed W: Vanadium-induced kappa B-dependent transcription depends upon peroxide-induced activation of the p38 mitogen-activated protein kinase. Am J Respir Cell Mol Biol 23: 95-102, 2000.
69. Takenaga K: Suppression of metastatic potential of high-metastatic Lewis lung carcinoma cells by vanadate, an inhibitor of tyrosine phosphatase, through inhibiting cell-substrate adhesion. Invasion Metastasis 16: 97-106, 1996.
70. Dhawan S, Singh S and Aggarwal BB: Induction of endothelial cell surface adhesion molecules by tumor necrosis factor is blocked by protein tyrosine phosphatase inhibitors: role of the nuclear transcription factor NF-kappa B. Eur J Immunol 27: 2172-2179, 1997.
71. Luber B, Candidus S, Handschuh G, Mentele E, Hutzler P, Feller S, Voss J, Hofler H and Becker KF: Tumor-derived mutated E-cadherin influences beta-catenin localization and increases susceptibility to actin cytoskeletal changes induced by pervanadate. Cell Adhes Commun 7: 391-408, 2000.
72. Cohen N, Halberstam M, Shlimovich P, Chang CJ, Shamoon H and Rossetti L: Oral vanadyl sulfate improves hepatic and peripheral insulin sensitivity in patients with non-insulin-dependent diabetes mellitus. J Clin Invest 95: 2501-2509, 1995.
73. Boden G, Chen X, Ruiz J, van Rossum GD and Turco S: Effects of vanadyl sulfate on carbohydrate and lipid metabolism in patients with non-insulin-dependent diabetes mellitus. Metabolism 45: 1130-1135, 1996.
74. Fawcett JP, Farquhar SJ, Thou T and Shand BI: Oral vanadyl sulphate does not affect blood cells, viscosity or biochemistry in humans. Pharmacol Toxicol 80: 202-206, 1997.
75. Ivancsits S, Pilger A, Diem E and Rudiger HW: Vanadate induces DNA strand breaks in cultured human fibroblasts at doses relevant to occupational exposure. Mutat Res 26: 25-35, 2002.
76. Wang F, Elliott RL and Head JF: Inhibitory effect of deferoxamine mesylate and low iron diet on the 13762NF rat mammary adenocarcinoma. Anticancer Res 19: 445-450, 1999.
77. Kemp JD, Cardillo T, Stewart BC, Kehrberg E, Weiner G, Hedlund B and Naumann PW: Inhibition of lymphoma growth in vivo by combined treatment with hydroxyethyl starch deferoxamine conjugate and IgG monoclonal antibodies against the transferrin receptor. Cancer Res 55: 3817-3824, 1995.
78. Burger RM, Adler AD, Horwitz SB, Mims WB and Peisach J: Demonstration of nitrogen coordination in metalbleomycin complexes by electron spin-echo envelope spectroscopy. Biochemistry 20: 1701-1704, 1981.
79. Takeda E and Weber G: Role of ribonucleotide reductase in expression in the neoplastic program. Life Sci 28: 1007-1014, 1981.
80. Richardson DR: Potential of iron chelators as effective antiproliferative agents. Can J Physiol Pharmacol 75: 1164-1180, 1997.
81. Donfrancesco A, Deb G, De Sio L, Cozza R and Castellano A: Role of deferoxamine in tumor therapy. Acta Haematol 95: 66-69, 1996.
82. Becton DL and Bryles P: Deferoxamine inhibition of human neuroblastoma viability and proliferation. Cancer Res 48: 7189-7192, 1988.
83. Estrov Z, Tawa A, Wang XH, Dube ID, Sulh H, Cohen A, Gelfand EW and Freedman MH: In vitro and in vivo effects of deferoxamine in neonatal acute leukemia. Blood 69: 757-761, 1987.
84. Oexle H, Gnaiger E and Weiss G: Iron-dependent changes in cellular energy metabolism: influence on citric acid cycle and oxidative phosphorylation. Biochim Biophys Acta 1413: 99-107, 1999.
85. Finch RA, Liu M, Grill SP, Rose WC, Loomis R, Vasquez KM, Cheng Y and Sartorelli AC: Triapine (3-aminopyridine-2-carboxaldehyde-thiosemicarbazone): A potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity. Biochem Pharmacol 59: 983-991, 2000.
86. Pickart L, Goodwin WH, Burgua W, Murphy TB and Johnson DK: Inhibition of the growth of cultured cells and an implanted fibrosarcoma by aroylhydrazone analogs of the Gly-His-Lys-Cu(II) complex. Biochem Pharmacol 32: 3868-3871, 1983.
87. Richardson DR and Bernhardt PV: Crystal and molecular structure of 2-hydroxy-1-naphthaldehyde isonicotinoyl hydrazone (NIH) and its iron(III) complex: an iron chelator with anti-tumour activity. J Biol Inorg Chem 4: 266-273, 1999.
88. Darnell G and Richardson DR: The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents III: the effect of the ligands on molecular targets involved in proliferation. Blood 94: 781-792, 1999.
89. Gao J, Lovejoy D and Richardson DR: Effect of iron chelators with potent anti-proliferative activity on the expression of molecules involved in cell cycle progression and growth. Redox Rep 4: 311-312, 1999.
90. Torti SV, Torti FM, Whitman SP, Brechbiel MW, Park G and Planalp RP: Tumor cell cytotoxicity of a novel metal chelator. Blood 92: 1384-1389, 1998.
91. Rakba N, Loyer P, Gilot D, Delcros JG, Glaise D, Baret P, Pierre JL, Brissot P and Lescoat G: Antiproliferative and apoptotic effects of O-Trensox, a new synthetic iron chelator, on differentiated human hepatoma cell lines. Carcinogenesis 21: 943-951, 2000.
92. Richardson DR: Iron chelators as therapeutic agents for the treatment of cancer. Crit Rev Oncol Hematol 42: 267-281, 2002.
93. Katsaros N and Anagnostopoulou A: Rhodium and its compounds as potential agents in cancer treatment. Crit Rev Oncol Hematol 42: 297-308, 2002.
94. Howard RA, Kimball AP and Bear JL: Mechanism of action of tetra-mu-carboxylatodirhodium(II) in L1210 tumor suspension culture. Cancer Res 39: 2568-2573, 1979.
95. Howard RA, Spring TG and Bear JL: The interaction of rhodium(II) carboxylates with enzymes. Cancer Res 36: 4402-4405, 1976.
96. Chibber R, Stratford IJ, O'Neill P, Sheldon PW, Ahmed I and Lee B: The interaction between radiation and complexes of cis-Pt(II) and Rh(II): studies at the molecular and cellular level. Int J Radiat Biol Relat Stud Phys Chem Med 48: 513-524, 1985.
97. Giraldi T, Zassinovich G and Mestroni G: Antitumour action of planar, organometallic rhodium(I) complexes. Chem Biol Interact 9: 389-394, 1974.
98. Giraldi T, Sava G, Bertoli G, Mestroni G and Zassinovich G: Antitumor action of two rhodium and ruthenium complexes in comparison with cis-diamminedichloroplatinum(II). Cancer Res 37: 2662-2666, 1977.
99. McCully KS and Vezeridis MP: Antineoplastic activity of a rhodium trichloride complex of oxalyl homocysteine thiolactone. Cancer Invest 5: 25-30, 1987.
100. Jackson BA, Alekseyev VY and Barton JK: A versatile mismatch recognition agent: specific cleavage of a plasmid DNA at a single base mispair. Biochemistry 38: 4655-4662, 1999.
101. Lommatzsch PK and Kirsch IH: 106Ru/106Rh plaque radiotherapy for malignant melanomas of the choroid. With follow-up results more than 5 years. Doc Ophthalmol 68: 225-238, 1988.
102. Ballin R, Lommatzsch PK, Drost H and Ratajek B: A beta ray applicator (106Ru/106Rh) in the treatment of ciliary body melanomas. Klin Monatsbl Augenheilkd 187: 144-146, 1985.
103. Brooks RC, Carnochan P, Vollano JF, Powell NA, Zweit J, Sosabowski JK, Martellucci S, Darkes MC, Fricker SP and Murrer BA: Metal complexes of bleomycin: evaluation of [Rh-105]-bleomycin for use in targeted radiotherapy. Nucl Med Biol 26: 421-430, 1999.
104. Clarke MJ, Zhu F and Frasca DR: Non-platinum chemotherapeutic metallopharmaceuticals. Chem Rev 99: 2511-2534, 1999.
105. Kopf H and Kopf-Maier P: Titanocene dichloride-the first metallocene with cancerostatic activity. Angew Chem Int Ed Engl 18: 477-478, 1979.
106. Kopf-Maier P: Complexes of metals other than platinum as antitumour agents. Eur J Clin Pharmacol 47: 1-16, 1994.
107. Christodoulou CV, Ferry DR, Fyfe DW, Young A, Doran J, Sheehan TM, Eliopoulos A, Hale K, Baumgart J, Sass G and Kerr DJ: Phase I trial of weekly scheduling and pharmacokinetics of titanocene dichloride in patients with advanced cancer. J Clin Oncol 16: 2761-2769, 1998.
108. Schilling T, Keppler KB, Heim ME, Niebch G, Dietzfelbinger H, Rastetter J and Hanauske AR: Clinical phase I and pharmacokinetic trial of the new titanium complex budotitane. Invest New Drugs 13: 327-332, 1996.
109. Korfel A, Scheulen ME, Schmoll HJ, Grundel O, Harstrick A, Knoche M, Fels LM, Skorzec M, Bach F, Baumgart J, Sass G, Seeber S, Thiel E and Berdel WE: Phase I clinical and pharmacokinetic study of titanocene dichloride in adults with advanced solid tumors. Clin Cancer Res 4: 2701-2708, 1998.
110. Harstrick A, Schmoll HJ, Sass G, Poliwoda H and Rustum Y: Titanocendichloride activity in cisplatin and doxorubicin-resistant human ovarian carcinoma cell lines. Eur J Cancer 29A: 1000-1002, 1993.
111. Christodoulou CV, Eliopoulos AG, Young LS, Hodgkins L, Ferry DR and Kerr DJ: Anti-proliferative activity and mechanism of action of titanocene dichloride. Br J Cancer 77: 2088-2097, 1998.
112. Melendez E: Titanium complexes in cancer treatment. Crit Rev Oncol Hematol 42: 309-315, 2002.
113. Kopf-Maier P and Tornieporth-Oetting IC: Antitumor activity of titanocene amino acid complexes. Biometals 9: 267-271, 1996.
114. Harding MM and Mokdsi G: Antitumour metallocenes: structure-activity studies and interactions with biomolecules. Curr Med Chem 7: 1289-1303, 2000.
115. Guo M, Sun H, McArdle HJ, Gambling L and Sadler PJ: Ti(IV) uptake and release by human serum transferrin and recognition of Ti(IV)-transferrin by cancer cells: understanding the mechanism of action of the anticancer drug titanocene dichloride. Biochemistry 39: 10023-10033, 2000.
116. Green MA and Welch MJ: Gallium radiopharmaceutical chemistry. Int J Rad Appl Instrum B 16: 435-448, 1989.
117. Hart MM and Adamson RH: Antitumor activity and toxicity of salts of inorganic group 3a metals: aluminum, gallium, indium, and thallium. Proc Natl Acad Sci USA 68: 1623-1626, 1971.
118. Hart MM, Smith CF, Yancey ST and Adamson RH: Toxicity and antitumor activity of gallium nitrate and periodically related metal salts. J Natl Cancer Inst 47: 1121-1127, 1971.
119. MANFAIT M and Collery P: Etude in vitro par spectroscopie Raman de la conformation d'un ADN sous l'influence des ions magnésium et gallium. Magnesium Bull 4: 153-155, 1984.
120. Hedley DW, Tripp EH, Slowiaczek P and Mann GJ: Effect of gallium on DNA synthesis by human T-cell lymphoblasts. Cancer Res 48: 3014-3018, 1988.
121. Chitambar CR, Matthaeus WG, Antholine WE, Graff K and O'Brien WJ: Inhibition of leukemic HL60 cell growth by transferrin-gallium: effects on ribonucleotide reductase and demonstration of drug synergy with hydroxyurea. Blood 72: 1930-1936, 1988.
122. Hayes RL, Rafter JJ, Byrd BL and Carlton JE: Studies of the in vivo entry of Ga-67 into normal and malignant tissue, J Nucl Med 22: 325-332, 1981.
123. Larson SM, Grunbaum Z and Rasey JS: The role of transferrins in gallium uptake. Int J Nucl Med Biol 8: 257-266, 1981.
124. Weiner RE, Schreiber GJ and Hoffer PB: In vitro transfer of Ga-67 from transferrin to ferritin. J Nucl Med 24: 608-614, 1983.
125. Weiner RE: Role of phosphate-containing compounds in the transfer of indium-111 and gallium-67 from transferrin to ferritin. J Nucl Med 30: 70-79, 1989.
126. Rasey JS, Nelson NJ and Larson SM: Tumor cell toxicity of stable gallium nitrate: enhancement by transferrin and protection by iron. Eur J Cancer Clin Oncol 18: 661-668, 1982.
127. Anghileri LJ, Maleki P, Cordova MA, Crone-Escanye MC and Robert J: The role of the interaction between Fe(III) and cell surface in the accumulation of 67Ga by tumor cells. Nuklearmedizin 30: 290-293, 1991.
128. Kovar J, Seligman P and Gelfand EW: Differential growth-inhibitory effects of gallium on B-lymphocyte lines in high versus low iron concentrations. Cancer Res 50: 5727-5730, 1990.
129. Rasey JS, Nelson NJ and Larson SM: Relationship of iron metabolism to tumor cell toxicity of stable gallium salts. Int J Nucl Med Biol 8: 303-313, 1981.
130. Sephton R and Martin JJ: Modification of distribution of gallium 67 in man by administration of iron. Br J Radiol 53: 572-575, 1980.
131. Sephton R and De Abrew S: Mechanism of gallium uptake in tumours. In: Metal Ions in Biology and Medicine (Collery P, Poirier LA, Manfait M and Etienne JC ed) Paris, John Libbey Eurotext, 1990, pp 393.
132. Shukla SK and Cipriani C: Protonation of hexamethylenetetramine by GaCl3. xH20 and growth inhibition effect on K562 cells. In: Metal Ions in Biology and Medicine (Collery Ph, Poirier LA, Manfait M and Etienne JC, ed). Paris, John Libbey Eurotext, 1990, pp 533-537.
133. Smith FW and Dendy PP: Modification of gallium-67 citrate distribution in man following the administration of iron. Br J Radiol 54: 398-402, 1981.
134. Ohkubo Y, Araki S, Abe K, Takasu S, Kohno H and Kubodera A: The effect of FeCl3 on the accumulation of gallium-67 into inflammatory and normal tissues. Ann Nucl Med 2: 59-62, 1988.
135. Chitambar CR, Zivkovic-Gilgenbach Z, Narasimhan J and Antholine WE: Development of drug resistance to gallium nitrate through modulation of cellular iron uptake. Cancer Res 50: 4468-4472, 1990.
136. Lundberg JH and Chitambar CR: Interaction of gallium nitrate with fludarabine and iron chelators: effects on the proliferation of human leukemic HL60 cells. Cancer Res 50: 6466-6470, 1990.
137. Collery P, Millart H, Simoneau JP, Pluot M, Halpern S, Vistelle R, Lamiable D, Choisy H, Coudoux P and Etienne JC: Selective uptake of gallium administered orally, as chloride, by tumor cells. In: New Concepts in Cancer Chemotherapy (Spitzy KH and Kaner K, ed). 1983, pp 35-43.
138. Collery P, Millart H, Simoneau JP, Pluot M, Halpern S, Pechery C, Choisy H and Etienne JC: Experimental treatment of mammary carcinomas by Gallium chloride after oral administration: intratumor dosages of Gallium, anatomo-pathologic study and intracellular micro-analysis. Trace Elem Med 1: 159-161, 1984.
139. Collery P: Gallium Compounds in Cancer Therapy. Chapter 8: 237-263, London, Chapman and Hall Ltd Scientific, Technical and Medical Publishers, 1994.
140. Knorr GM and Chitambar CR: Gallium-pyridoxal isonicotinoyl hydrazone (Ga-PIH), a novel cytotoxic gallium complex. A comparative study with gallium nitrate. Anticancer Res 18: 1733-1737, 1998.
141. Collery P, Lechenault F, Cazabat A, Juvin E, Khassanova L, Evangelou A and Keppler B: Inhibitory effects of gallium chloride and tris (8-quinolinolato) gallium III on A549 human malignant cell line. Anticancer Res 20: 955-958, 2000.
142. Thiel M, Schilling T, Gey DC, Ziegler R, Collery P and Keppler BK: Tris(8-quinolinolato)gallium(III), a novel orally applied antitumor gallium compound. In: Relevance of Tumor Models for Anticancer Drug Development. Basel, Karger, 1999, pp 439-443.
143. Desoize B, Keppler BK, Akéli MG, Etienne JC and Collery P: Tris(8-quinolinolato)Ga(III) is active against unicellular and multicellular resistance. In: Metal Ions in Biology and Medicine (Centeno JA and Collery P). Paris, John Libbey Eurotext, 2000, pp 573-576.
144. Desoize B and Jardillier J: Multicellular resistance: a paradigm for clinical resistance? Crit Rev Oncol Hematol 36: 193-207, 2000.
145. Wang F, Jiang X, Yang DC, Elliott RL and Head JF: Doxorubicin-gallium- transferrin conjugate overcomes multidrug resistance: evidence for drug accumulation in the nucleus of drug resistant MCF-7/ADR cells. Anticancer Res 20: 799-808, 2000.
146. Carpentier Y, Liautaud-Roger F, Collery P, Loirette M, Desoize B and Coninx P: Effect of gallium on the cell cycle of tumor cells in vitro. In: Metal Ions in Biology and Medicine (Collery Ph, Poirier LA, Manfait M and Etienne JC, ed). Paris, John Libbey Eurotext, 1990, pp 406-408.
147. Warrell RP Jr, Skelos A, Alcock NW and Bockman RS: Gallium nitrate for acute treatment of cancer-related hypercalcemia: clinicopharmacological and dose response analysis. Cancer Res 46: 4208-4212, 1986.
148. Warrell RP Jr, Issacs M, Alcock NW and Bockman RS: Gallium nitrate for treatment of refractory hypercalcemia from parathyroid carcinoma. Ann Intern Med 107: 683-686, 1987.
149. Warrell RP Jr, Israel R, Frisone M, Snyder T, Gaynor JJ and Bockman RS: Gallium nitrate for acute treatment of cancer-related hypercalcemia. A randomized, double-blind comparison to calcitonin. Ann Intern Med 108: 669-674, 1988.
150. Warrell RP Jr: Questions about clinical trials in hypercalcemia [editorial]. J Clin Oncol 6: 759-761, 1988.
151. Warrell RP and Bockman RS: Gallium for bone loss in cancer and metabolic bone diseases. In: Metal Ions in Biology and Medicine (Collery P, Poirier LA, Manfait M and Etienne JC, ed). Paris, John Libbey Eurotext, 1990, pp 432-435.
152. Todd PA and Fitton A: Gallium nitrate. A review of its pharmacological properties and therapeutic potential in cancer related hypercalcaemia. Drugs 42: 261-273, 1991.
153. Repo MA, Bockman RS, Betts F, Boskey AL, Alcock NW and Warrell RP Jr: Effect of gallium on bone mineral properties. Calcif Tissue Int 43: 300-306, 1988.
154. Whitacre C, Apseloff G, Cox K, Matkovic V, Jewell S and Gerber N: Suppression of experimental autoimmune encephalomyelitis by gallium nitrate. J Neuroimmunol 39: 175-181, 1992.
155. Hall TJ and Chambers TJ: Gallium inhibits bone resorption by a direct effect on osteoclasts. Bone Miner 8: 211-216, 1990.
156. Cournot-Witmer G, Bourdeau A, Lieberherr M, Thil CL, Plachot JJ, Enault G, Bourdon R and Balsan S: Bone modeling in gallium nitrate-treated rats. Calcif Tissue Int 40: 270-275, 1987.
157. Collery P and Perdu D: Bone reconstruction of a lytic rib metastase after chemotherapy with cisplatinum, etoposide and gallium in a lung cancer patient. In: Metal Ions in Biology and Medicine (Anastassopoulou J, Collery Ph, Etienne JC and Theophanides Th Eds, ed). Paris, John Libbey Eurotext, 1992, pp 180-181.
158. Bockman RS, Boskey AL, Blumenthal NC, Alcock NW and Warrell RP Jr: Gallium increases bone calcium and crystallite perfection of hydroxyapatite. Calcif Tissue Int 39: 376-381, 1986.
159. Warrell RP Jr, Bosco B, Weinerman S, Levine B, Lane J and Bockman RS: Gallium nitrate for advanced Paget disease of bone: effectiveness and dose-response analysis. Ann Intern Med 113: 847-851, 1990.
160. Bockman RS, Adelman R, Donnell Y, Brody L, Warrell RP, and Jones K: Gallium, a unique anti-resorptive agent in bones: preclinical studies on its mechanisms of action. In: Metal Ions in Biology and Medicine (Collery Ph, Poirier LA, Manfait M, Etienne JC, ed). Paris, John Libbey Eurotext, 1990, pp 426-431.
161. Seligman PA and Crawford ED: Treatment of advanced transitional cell carcinoma of the bladder with continuous-infusion gallium nitrate. J Natl Cancer Inst 83: 1582-1584, 1991.
162. Seidman AD, Scher HI, Heinemann MH, Bajorin DF, Sternberg CN, Dershaw DD, Silverberg M and Bosl GJ: Continuous infusion gallium nitrate for patients with advanced refractory urothelial tract tumors. Cancer 68: 2561-2565, 1991.
163. Danieu L, Atkins C, Sykes M and Warrell RP: Gallium nitrate, methyl-GAG and etoposide: an effective investigational combination for relapsed lymphoma. Proc ASCO 4: 209-1985.
164. Warrell RP Jr, Coonley CJ, Straus DJ and Young CW: Treatment of patients with advanced malignant lymphoma using gallium nitrate administered as a seven-day continuous infusion. Cancer 51: 1982-1987, 1983.
165. Warrell RP Jr, Danieu L, Coonley CJ and Atkins C: Salvage chemotherapy of advanced lymphoma with investigational drugs: mitoguazone, gallium nitrate, and etoposide. Cancer Treat Rep 71: 47-51, 1987.
166. Warrell RP Jr: Gallium nitrate for the treatment of bone metastases. Cancer 80: 1680-1685, 1997.
167. Collery P, Millart H, Lamiable D, Vistelle R, Rinjard P, Tran G, Gourdier B, Cossart C, Bouana JC and Pechery C: Clinical pharmacology of gallium chloride after oral administration in lung cancer patients. Anticancer Res 9: 353-356, 1989.
168. Collery P, Morel M, Millart H, Desoize B, Cossart C, Perdu D, Vallerand H, Bouana JC, Pechery C, Etienne JC, Choisy H and Dubois de Montreynaud JM: Oral administration of gallium in conjunction with platinum in lung cancer treatment. In: Metal Ions in Biology and Medicine (Collery P, Poirier LA, Manfait M and Etienne JC, ed). Paris, John Libbey Eurotext, 1990, pp 437-442.
169. Collery P, Morel M, Desoize B, Millart H, Perdu D, Prevost A, Vallerand H, Pechery C, Choisy H and Etienne JC: Combination chemotherapy with cisplatin, etoposide and gallium chloride for lung cancer: individual adaptation of doses. Anticancer Res 11: 1529-1532, 1991.
170. Collery P, Vallerand H, Prevost A, Milosevic D, Morel M, Dubois JP, Desoize B, Pechery C, Dubois de Montreynaud JM, Millart H and Choisy H: Therapeutic index of gallium, orally administered, as chloride, in combination with cisplatinum and etoposide in lung cancer patients. In: Metal Ions in Biology and Medicine (Anastassopoulou J, Collery Ph, Etienne JC and Theophanides Th, ed). Paris, John Libbey Eurotext, 1992, pp 167-172.
171. Collery P and Pechery C: Clinical experience with tumor-inhibiting gallium complexes. In: Metal Complexes in Cancer Chemotherapy (Keppler BK, Weinheim VCH, ed). 1993, pp 249-258.
172. Hata Y, Sandler A, Loehrer PJ, Sledge GW Jr and Weber G: Synergism of taxol and gallium nitrate in human breast carcinoma cells: schedule dependency. Oncol Res 6: 19-24, 1994.
173. Myette MS, Elford HL and Chitambar CR: Interaction of gallium nitrate with other inhibitors of ribonucleotide reductase: effects on the proliferation of human leukemic cells. Cancer Lett 129: 199-204, 1998.
174. Collery P, Lechenault F, Juvin E, Khassanova L, Vernet G, Cazabat A and Lebargy F: Synergistic effects between gallium chloride and vinorelbine on U937 malignant cell lines. In: Metal Complexes in Cancer Chemotherapy (Collery P, Brätter P, Negretti de Brätter P, Khassanova L, Etienne JC, ed). 1998, pp 588-593.
175. Chitambar CR, Wereley JP and Riaz uH: Synergistic inhibition of T-lymphoblastic leukemic CCRF-CEM cell growth by gallium and recombinant human alpha-interferon through action on cellular iron uptake. Cancer Res 54: 3224-3228, 1994.
176. Chitambar CR, Zahir SA, Ritch PS and Anderson T: Evaluation of continuous-infusion gallium nitrate and hydroxyurea in combination for the treatment of refractory non-Hodgkin's lymphoma. Am J Clin Oncol 20: 173-178, 1997.
177. Rosenberg B, Van Camp L and Krigas T: Inhibition of cell division in Escherichia coli by electrolysis products from platinum electrode. Nature 205: 698-699, 1965.
178. Desoize B and Madoulet C: Particular aspects of platinum compounds used at present in cancer treatment. Crit Rev Oncol Hematol 42: 317-325, 2002.
179. Fichtinger-Schepman AM, Dijt FJ, De Jong WH, Van Oosterom AT and Brends F: In vivo cisplatin-DNA adducts formation and removals as measured with immunochemical techniques. In: Platinum and Other Metal Coordination Compounds in Cancer Chemotheray (Nicolini M, ed). Boston, Martinum Nijhoff, 1988, pp 32-46.
180. Szymkowski DE, Yarema K, Essigmann JM, Lippard SJ and Wood RD: An intrastrand d(GpG) platinum crosslink in duplex M13 DNA is refractory to repair by human cell extracts. Proc Natl Acad Sci USA 89: 10772-10776, 1992.
181. Mello JA, Lippard SJ and Essigmann JM: DNA adducts of cis-diamminedichloroplatinum(II) and its trans isomer inhibit RNA polymerase II differentially in vivo. Biochemistry 34: 14783-14791, 1995.
182. Suo Z, Lippard SJ and Johnson KA: Single d(GpG)/cis-diammineplatinum(II) adduct-induced inhibition of DNA polymerization. Biochemistry 38: 715-726, 1999.
183. Zamble DB and Lippard SJ: Cisplatin and DNA repair in cancer chemotherapy. Trends Biochem Sci 20: 435-439, 1995.
184. Akaboshi M, Kawai K, Kinashi Y, Masunaga S and Ono K: Relationship between cell-killing efficiency and number of platinum atoms binding to DNA, RNA, and protein molecules in HeLa cells treated with cis-diamine(glycolato) platinum(II). Jpn J Cancer Res 87: 178-183, 1996.
185. Plooy AC, van Dijk M, Berends F and Lohman PH: Formation and repair of DNA interstrand cross-links in relation to cytotoxicity and unscheduled DNA synthesis induced in control and mutant human cells treated with cis-diamminedichloroplatinum(II). Cancer Res 45: 4178-4184, 1985.
186. Dabholkar M, Vionnet J, Bostick-Bruton F, Yu JJ and Reed E: Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J Clin Invest 94: 703-708, 1994.
187. Fink D, Aebi S and Howell SB: The role of DNA mismatch repair in drug resistance. Clin Cancer Res 4: 1-6, 1998.
188. Cvitkovic E: Ongoing and unsaid on oxaliplatin: the hope. Br J Cancer 77 Suppl 4: 8-11, 1998.
189. Desoize B: Anticancer drug resistance and inhibition of apoptosis. Anticancer Res 14: 2291-2294, 1994.
190. Minn AJ, Rudin CM, Boise LH and Thompson CB: Expression of bcl-xL can confer a multidrug resistance phenotype. Blood 86: 1903-1910, 1995.
191. Simonian PL, Grillot DA and Nunez G: Bcl-2 and Bcl-XL can differentially block chemotherapy-induced cell death. Blood 90: 1208-1216, 1997.
192. Nagane M, Levitzki A, Gazit A, Cavenee WK and Huang HJ: Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases. Proc Natl Acad Sci USA 95: 5724-5729, 1998.
193. Akiyama S, Chen ZS, Sumizawa T and Furukawa T: Resistance to cisplatin. Anticancer Drug Des 14: 143-151, 1999.
194. Kelland LR: Preclinical perspectives on platinum resistance [In Process Citation]. Drugs 59 Suppl 4: 1-8, 2000.
195. Lebwohl D and Canetta R: Clinical development of platinum complexes in cancer therapy: an historical perspective and an update. Eur J Cancer 34: 1522-1534, 1998.
196. O'Dwyer PJ, Stevenson JP and Johnson SW: Clinical pharmacokinetics and administration of established platinum drugs [In Process Citation]. Drugs 59 Suppl 4: 19-27, 2000.
197. Go RS and Adjei AA: Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol 17: 409-422, 1999.
198. Lokich J and Anderson N: Carboplatin versus cisplatin in solid tumors: an analysis of the literature [published erratum appears in Ann Oncol 9 (3): 341,1998]. Ann Oncol 9: 13-21, 1998.
199. Lokich J and Anderson N: Carboplatin versus cisplatin in solid tumors: an analysis of the literature [published erratum appears in Ann Oncol 9 (3): 341,1998]. Ann Oncol 9: 13-21, 1998.
200. Advanced Ovarian Cancer Trialists Group: Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Advanced Ovarian Cancer Trialists Group [see comments]. BMJ 303: 884-893, 1991.
201. Raymond E, Chaney SG, Taamma A and Cvitkovic E: Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol 9: 1053-1071, 1998.
202. Graham MA, Lockwood GF, Greenslade D, Brienza S, Bayssas M and Gamelin E: Clinical pharmacokinetics of oxaliplatin: a critical review [In Process Citation]. Clin Cancer Res 6: 1205-1218, 2000.
203. Levi F, Metzger G, Massari C and Milano G: Oxaliplatin: pharmacokinetics and chronopharmacological aspects. Clin Pharmacokinet 38: 1-21, 2000.
204. Misset JL: Oxaliplatin in practice. Br J Cancer 77 Suppl 4: 4-7, 1998.
205. Boughattas NA, Levi F, Fournier C, Lemaigre G, Roulon A, Hecquet B, Mathe G and Reinberg A: Circadian rhythm in toxicities and tissue uptake of 1,2-diamminocyclohexane(trans-1)oxalatoplatinum(II) in mice. Cancer Res 49: 3362-3368, 1989.
206. Caussanel JP, Levi F, Brienza S, Misset JL, Itzhaki M, Adam R, Milano G, Hecquet B and Mathe G: Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate. J Natl Cancer Inst 82: 1046-1050, 1990.
207. de Gramont A, Bosset JF, Milan C, Rougier P, Bouche O, Etienne PL, Morvan F, Louvet C, Guillot T, Francois E and Bedenne L: Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 15: 808-815, 1997.
208. Maindrault-Goebel F, Louvet C, Andre T, Carola E, Lotz JP, Molitor JL, Garcia ML, Gilles-Amar V, Izrael V, Krulik M and de Gramont A: Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR. Eur J Cancer 35: 1338-1342, 1999.
209. Sasaki Y, Amano T, Morita M, Shinkai T, Eguchi K, Tamura T, Ohe Y, Kojima A and Saijo N: Phase I study and pharmacological analysis of cis-diammine(glycolato)platinum (254-S; NSC 375101D) administered by 5-day continuous intravenous infusion. Cancer Res 51: 1472-1477, 1991.
210. Sasaki Y, Tamura T, Eguchi K, Shinkai T, Fujiwara Y, Fukuda M, Ohe Y, Bungo M, Horichi N and Niimi S: Pharmacokinetics of (glycolate-0,0′)- diammine platinum (II), a new platinum derivative, in comparison with cisplatin and carboplatin. Cancer Chemother Pharmacol 23: 243-246, 1989.
211. Desoize B: Metal and metal compounds in carcinogenesis. Part I. In Vivo 17: 529-540, 2003.